


BMS-248360

Cat. No.:	HY-114953
CAS No.:	254737-87-6
Molecular Formula:	C ₃₆ H ₄₅ N ₅ O ₅ S
Molecular Weight:	659.84
Target:	Angiotensin Receptor; Endothelin Receptor
Pathway:	GPCR/G Protein
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	BMS-248360 is a potent and orally active dual antagonist of both angiotensin II receptor (AT ₁) and endothelin A (ET _A) receptor, with K _i s of 10 nM and 1.9 nM for hAT ₁ and hETA receptor, respectively. BMS-248360 displays hypertensive effects ^[1] .																	
IC₅₀ & Target	K _i : 10 nM (hAT ₁), 1.9 nM (hETA receptor), 6.0 nM (rAT ₁), 1.9 nM (rET _A receptor) ^[1]																	
In Vitro	BMS-248360 shows activity against rat AT ₁ and rat ET _A receptor, with K _i s of 6.0 nM and 1.9 nM, respectively ^[1] . BMS-248360 shows no activity against AT ₂ and ET _B receptor subtypes ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.																	
In Vivo	<p>BMS-248360 is found to be orally bioavailable in rats (%F=38) with excellent oral exposure (C_{max})=3.1 μM and reasonable elimination profile (T_{1/2}=5.5 hours)^[1].</p> <p>BMS-248360 (30 μmol/kg, 100 μmol/kg; p.o.) blocks the hypertensive effects of intravenously administered All^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Male Rats^[1]</td> </tr> <tr> <td>Dosage:</td> <td>30 μM/kg, 100 μM/kg</td> </tr> <tr> <td>Administration:</td> <td>Oral administration</td> </tr> <tr> <td>Result:</td> <td>Blocked the hypertensive effects of intravenously administered All.</td> </tr> </table> <table border="1"> <tr> <td>Animal Model:</td> <td>Male Rats^[1]</td> </tr> <tr> <td>Dosage:</td> <td>10 μM/kg</td> </tr> <tr> <td>Administration:</td> <td>Oral administration</td> </tr> <tr> <td>Result:</td> <td>T_{1/2}= 5.5 hours</td> </tr> </table>		Animal Model:	Male Rats ^[1]	Dosage:	30 μM/kg, 100 μM/kg	Administration:	Oral administration	Result:	Blocked the hypertensive effects of intravenously administered All.	Animal Model:	Male Rats ^[1]	Dosage:	10 μM/kg	Administration:	Oral administration	Result:	T _{1/2} = 5.5 hours
Animal Model:	Male Rats ^[1]																	
Dosage:	30 μM/kg, 100 μM/kg																	
Administration:	Oral administration																	
Result:	Blocked the hypertensive effects of intravenously administered All.																	
Animal Model:	Male Rats ^[1]																	
Dosage:	10 μM/kg																	
Administration:	Oral administration																	
Result:	T _{1/2} = 5.5 hours																	

REFERENCES

[1]. Murugesan N, et al. Discovery of N-isoxazolyl biphenylsulfonamides as potent dual angiotensin II and endothelin A receptor antagonists. J Med Chem. 2002 Aug 29;45(18):3829-35.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA